Repositioning Candidate Details
| Candidate ID: | R0773 |
| Source ID: | DB05336 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Obiltoxaximab |
| Synonyms: | Obiltoxaximab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. |
| CAS Number: | 1351337-07-9 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|